OIG Urges Look At Additional Part D Rebates
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress and CMS should “explore the costs and benefits” of additional Part D rebates, HHS Inspector General says after finding that rebates for selected brands were “substantially higher” for Medicaid than Medicare. But with GOP-controlled Congress, chances of passing mandatory rebates are slim.
You may also be interested in...
Part D Data Release Could Be Boon For Sales Forces
CMS released data with detailed information on the drugs individual physicians and other providers prescribed in 2013 under Medicare Part D, giving companies a new trove of information on who exactly is prescribing their drugs.
Medicaid Gets Higher Rebates For Brand Drugs Compared To Medicare Part D, OIG Says
Findings could carry extra significance as congressional "super committee" looks for ways to cut at least $1.2 trillion in federal spending.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.